This section provides essential news and information about Auxilium.

  • Press Releases - get the latest corporate information about Auxilium
  • Archive - see a complete listing of past press releases about Auxilium
  • Investor Kit - contact us to receive the latest investor relations information

For Investors - additional information and resources designed with investors in mind.

Recent News
Oct 20, 2014Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Now Approved For The Concurrent Treatment Of Up To Two Affected Joints In The Same Hand In Dupuytren's Contracture Patients
Estimated 35-40 Percent of Surgical Procedures to Treat DC Have Been Performed on Multiple Joints CHESTERBROOK, Pa., Oct. 20, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics Application (sBLA) for XIAFLEX® (collagenase clostridium histolyticum or CCH) for the treatment of up to two Dupuytren's contracture (DC) joints in the same ha... 
Printer Friendly Version
Oct 9, 2014Endo To Acquire Auxilium Pharmaceuticals In A Cash And Stock Transaction For Approximately $2.6 Billion
- Auxilium Shareholders to Receive $33.25 Per Share - Combination Designed to Create Leading Specialty Healthcare Company with Expanded Platform for Future Growth - Addition of Auxilium's Leading Men's Health Products and Development Portfolio Expected to Significantly Enhance Endo's Branded Pharmaceutical Business - Transaction Expected to be Immediately Accretive - Endo Expects to Generate up to $175 Million of Annual Run Rate Operating Expense Reductions Inclusive of the $75 Milli... 
Printer Friendly Version
Sep 22, 2014Auxilium Provides Transaction Update
Board Unanimously Reaffirms Recommendation of QLT Transaction CHESTERBROOK, Pa., Sept. 22, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that its Board of Directors (the "Board") has reviewed the unsolicited, non-binding and conditional proposal from Endo International plc ("Endo") and, after consulting with its independent financial and legal advisors, has unanimously determined it is not a superior proposal under... 
Printer Friendly Version
Sep 18, 2014Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting
Data Support CCH could be Used to Treat Two Affected Joints Concurrently; Positive Results Presented from Additional Studies Evaluating CCH Retreatment for Recurrent Contracture CHESTERBROOK, Pa., Sept. 18, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced the first presentation of positive safety and efficacy data from the AUX-CC-867 MULTICORD (MULtiple Treatment Investigation of Collagenase Optimizing the Resolution ... 
Printer Friendly Version